Therapy News and Research

RSS

St. Joseph's Hospital launches new neuromodulation center in Barrow

St. Joseph's Hospital and Medical Center's Barrow Neurological Institute has received a $10.1 million donation, the largest single gift in the organization's history and one of the biggest ever given to any Arizona hospital.

10 Mar 2011

AHF unveils new national advertising campaign about AIDS drugs

AIDS Healthcare Foundation today unveiled a new national advertising campaign headlined, "There Is No Magic Pill," an advocacy and awareness campaign to educate and prompt discussion among gay men and others regarding Gilead Sciences and its likely plans to seek Food and Drug Administration approval for use of its blockbuster AIDS drug Truvada as a form a 'pre-exposure prophylaxis' to prevent HIV transmission.

10 Mar 2011

U-M participates in national trial for alternative approach to open heart surgery for severe aortic stenosis

The University of Michigan Cardiovascular Center, a leader in heart valve replacement, will participate in a national clinical trial to offer patients a less invasive approach to replacing diseased aortic valves.

10 Mar 2011

CTI announces final pixantrone clinical trial design for treatment of DLBCL

Cell Therapeutics, Inc. today announced the final clinical trial design of a randomized pivotal trial of pixantrone for the treatment of diffuse large B-cell lymphoma following discussions with the U.S. Food and Drug Administration's Division of Hematologic Products.

10 Mar 2011

CDH Proton Center expands treatment capacity

The CDH Proton Center, A ProCure Center, in suburban Chicago, is now able to treat a wider variety of cancer tumors with the opening of a treatment room with a gantry, a nearly 100-ton rotating steel wheel that allows the proton beam to be directed at the tumor from any angle.

10 Mar 2011

FDA accepts Tris' Extended Release Carbinoxamine Oral Suspension NDA for allergies in kids

Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced today that the US Food and Drug Administration (FDA) has accepted its Extended Release Carbinoxamine Oral Suspension NDA for the treatment of allergies in kids two years and older. If approved, Tris Pharma's Extended Release Suspension will provide an alternative to the currently available immediate release formulations.

10 Mar 2011

Cedars-Sinai earns excellence in 2010 adult heart transplants

The Cedars-Sinai Heart Institute and Comprehensive Transplant Center performed the most adult heart transplants of any U.S. medical center in 2010, according to government statistics released today.

10 Mar 2011

Salmonella may serve as valuable tool to fight against cancer

University of Minnesota researchers are using salmonella - the bacteria commonly transmitted through food that sickens thousands of U.S. residents each year - to do what was once unthinkable: help people.

10 Mar 2011

Health Dialog unveils new Shared Decision Making program for insomnia patients

Health Dialog unveiled today a new Shared Decision Making program titled "Sleeping Better: Help for Long-Term Insomnia," to give patients information they need to make informed treatment decisions for this condition.

10 Mar 2011

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced that the U.S. Food and Drug Administration has approved BENLYSTA® (belimumab) for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.

10 Mar 2011

NeuroDerm commences ND0611 Phase I/II trial to treat Parkinson's disease

NeuroDerm, Ltd. announced today the enrollment of the first group of patients in its Phase I/II clinical trial of ND0611, a new patch for the treatment of Parkinson's disease.

9 Mar 2011

Camp STAR to offer evidence-based therapy for children with ADHD

Camp STAR, the Chicago area's only summer camp offering evidence-based therapy for children with Attention Deficit/Hyperactivity Disorder and other behavioral, emotional and social difficulties, begins its fourth season in June.

9 Mar 2011

Human Genome Sciences receives FDA approval for Benlysta to treat lupus

The U.S. Food and Drug Administration today approved Benlysta to treat patients with active, autoantibody-positive lupus who are receiving standard therapy, including corticosteroids, antimalarials, immunosuppressives, and nonsteroidal anti-inflammatory drugs.

9 Mar 2011

Alliance fourth quarter revenue decreases to $117.7 million

Alliance HealthCare Services, Inc., a leading national provider of outpatient diagnostic imaging and radiation therapy services, announced results for the fourth quarter and year ended December 31, 2010.

9 Mar 2011

Study finds passive smoking increases risk of still birth by 23%

Pregnant non-smokers who breathe in the second-hand smoke of other people are at an increased risk of delivering stillborn babies or babies with defects, a study led by researchers at The University of Nottingham has found.

9 Mar 2011

NovaShunt raises Series B financing for CHF 23.7 million

NovaShunt AG, a private Swiss medical device company with innovative fluid management technologies, announced today that it has raised CHF 23.7 million in a Series B preferred share financing round co-led by BioMedInvest AG, Entrepreneurs Fund and Capricorn Health-tech Fund.

9 Mar 2011

Vertex to present telaprevir and VX-222 study results against hepatitis C at EASL annual meeting

Vertex Pharmaceuticals Incorporated announced today that 15 abstracts on the company's medicines in development for hepatitis C, including its protease inhibitor, telaprevir, and polymerase inhibitor, VX-222, were accepted for presentation at the 46th Annual Meeting of the European Association for the Study of the Liver in Berlin, Germany, March 30 to April 3, 2011.

9 Mar 2011

Study supports DNA mismatch repair test for bowel cancer

Bowel cancer patients whose tumors contain defects in specific DNA repair systems are much less likely to experience tumour recurrence post surgery, results from a major clinical study have demonstrated.

9 Mar 2011

Wound Repair and Regeneration publishes positive findings from CXM's Matrix Phase 2b clinical study

Cardium Therapeutics today announced the publication of positive findings from the Company's Matrix Phase 2b clinical study.

9 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011